Erbin Dai Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Erbin Dai's research group focuses on the development of novel therapeutic strategies, particularly in the areas of thrombosis and drug-induced liver injury. Recent work has explored the synthesis and evaluation of glycomimetics and modified polysaccharides designed to inhibit platelet aggregation and reduce thrombus formation, with applications for blood-contacting devices. This includes the design of ultralow molecular weight heparin with enhanced resistance to biodegradation.
Further investigations address the challenges in measuring biomarkers for drug-induced liver injury, with a focus on liver-on-a-chip platforms. The group also studies the association between the gut microbiome and antituberculosis drug-induced liver injury, as well as the potential protective effects of anlotinib on radiation-induced lung injury through immune microenvironment modulation.
Dai has a h-index of 26, with 76 publications and 1,749 citations. Key collaborators include Tucker A. Patterson, James M. Oliphant, Katy S Papineau, and Lijun Ren, all from the National Center for Toxicological Research.
Metrics
- h-index: 26
- Publications: 76
- Citations: 1,761
Selected Publications
-
Challenges and solutions in measuring commonly used biomarkers for drug-induced liver injury in a liver-on-a-chip platform (2025)
Collaboration Network
Top Collaborators
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- A rechargeable anti-thrombotic coating for blood-contacting devices
- Sulfated poly-amido-saccharides (sulPASs) are anticoagulants <i>in vitro</i> and <i>in vivo</i>
- Total Synthesis of a PSGL-1 Glycopeptide Analogue for Targeted Inhibition of P-Selectin
- Design of an Ultralow Molecular Weight Heparin That Resists Heparanase Biodegradation
Showing 5 of 6 shared publications
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- A rechargeable anti-thrombotic coating for blood-contacting devices
- Sulfated poly-amido-saccharides (sulPASs) are anticoagulants <i>in vitro</i> and <i>in vivo</i>
- Total Synthesis of a PSGL-1 Glycopeptide Analogue for Targeted Inhibition of P-Selectin
- Design of an Ultralow Molecular Weight Heparin That Resists Heparanase Biodegradation
Showing 5 of 6 shared publications
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Total Synthesis of a PSGL-1 Glycopeptide Analogue for Targeted Inhibition of P-Selectin
- Intact quantitation and evaluation of a PEG-glycosulfopeptide as a therapeutic P-selectin antagonist
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Total Synthesis of a PSGL-1 Glycopeptide Analogue for Targeted Inhibition of P-Selectin
- Intact quantitation and evaluation of a PEG-glycosulfopeptide as a therapeutic P-selectin antagonist
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Intact quantitation and evaluation of a PEG-glycosulfopeptide as a therapeutic P-selectin antagonist
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Sulfated poly-amido-saccharides (sulPASs) are anticoagulants <i>in vitro</i> and <i>in vivo</i>
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Total Synthesis of a PSGL-1 Glycopeptide Analogue for Targeted Inhibition of P-Selectin
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Total Synthesis of a PSGL-1 Glycopeptide Analogue for Targeted Inhibition of P-Selectin
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Total Synthesis of a PSGL-1 Glycopeptide Analogue for Targeted Inhibition of P-Selectin
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Intact quantitation and evaluation of a PEG-glycosulfopeptide as a therapeutic P-selectin antagonist
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Total Synthesis of a PSGL-1 Glycopeptide Analogue for Targeted Inhibition of P-Selectin
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- Intact quantitation and evaluation of a PEG-glycosulfopeptide as a therapeutic P-selectin antagonist
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
- A rechargeable anti-thrombotic coating for blood-contacting devices
Similar Researchers
Based on overlapping research topics